BPC-157 Oral (tablets)

What it is

Same peptide as injectable BPC-157, pressed into a tablet. Swallowed, it lands on the stomach and gut lining, which is where the oral animal research was done and where people get the most from it. For a shoulder or an Achilles, the injection is still the form that was studied.

The tablet is for people whose problem is the gut: reflux that flares, a stomach that cannot handle ibuprofen anymore, cramping and loose stools after a bad course of antibiotics, the loose 'leaky gut' complaints that never get a diagnosis. It is also the form for people who want BPC-157 and will not inject, and for travel weeks when a vial and syringes are a hassle. A smaller group takes it alongside the injectable: shot at the injury, tablet for the gut.

Expect it to be quiet. For a gut that is irritated rather than diseased, the first thing people notice is that meals stop being an event: less burning after eating, fewer urgent trips, within a week or two. By week four most people who are going to respond have. It will not fix a tendon from the inside; nobody has measured how much of a swallowed dose reaches the bloodstream in a person, and the tendon data was generated with injections. If you take the tablet for a knee and feel nothing, the tablet is not the problem, the route is.

Run it on an empty stomach, 20 to 30 minutes before food, so it is sitting on the lining rather than mixed into a meal. One tablet a day is the standard tier; the higher tier is two, either together or morning and evening, which is what people do during a flare. A bottle of 100 is 100 days at one a day. Judge it over 4 to 8 weeks and keep going while the gut is still improving; there is no sign it stops working with daily use, and people with a long-running gut problem often stay on it for months. A pause now and then shows whether the calm holds, but the peptide does not need the break. The mistakes are predictable: swallowing it with breakfast, quitting at day ten because nothing dramatic happened, and expecting it to do what the injection does for a joint.

The evidence sits at animal 4, human 1. A surprising share of the classic BPC-157 rodent work used oral or intragastric dosing in gut injury models (NSAID and alcohol ulcers, colitis, fistulas) and it held up there, which is why the tablet is a reasonable gut tool rather than a marketing gimmick. BPC-157 is also unusually stable in gastric juice for a peptide, surviving more than a day in lab tests where most fall apart in minutes. Stable is not the same as absorbed, and there is no human trial for either route.

Skip the tablet if your goal is a tendon, ligament or a specific sore spot: use injectable BPC-157 at the site, where the cruise dose is the same 500 mcg but it is going where it needs to. If inflammation rather than lining damage is the main gut complaint, KPV oral or the BPC-157 + KPV blend covers it better. If you have diagnosed Crohn's, ulcerative colitis or an active ulcer under treatment, the tablet is an add-on at most, not a replacement for what your gastroenterologist prescribed. And with a cancer history, the tablet is the same hard stop as the injection, because of the new-blood-vessel effect.

What people use it for

Safety, in brief

The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.

Sources

The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.

1. Gastric pentadecapeptide BPC 157 and short bowel syndrome in ratsSever et al., Dig Dis Sci 2009 · Study
2. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157Sikiric et al., Curr Med Chem 2012 · Review
3. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone HealingSeiwerth et al., Curr Pharm Des 2018 · Review